BioMarin Extends Gene Therapy Leadership with DiNAQOR in a Preclinical Collaboration and License Agreement to Develop Gene Therapies for Rare Genetic Cardiomyopathies

SAN RAFAEL, Calif., May 3, 2020 /PRNewswire/ — BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the company has entered into a preclinical collaboration and license agreement with DiNAQOR AG (DiNAQOR), a gene therapy platform company, to develop novel gene therapies to treat rare genetic cardiomyopathies. DiNAQOR will receive an undisclosed upfront payment […]

DiNAQOR AG Announces Research Collaboration and License Agreement with UCL to Investigate Gene Therapies for Heart Failure

SAN FRANCISCO and PFÄFFIKON, Switzerland and LONDON, Jan. 13, 2020 /PRNewswire/ — DiNAQOR AG, a global gene therapy platform company, today announced a research collaboration and exclusive license agreement with UCL to develop novel gene therapies for the treatment of monogenic cardiomyopathies, diseases of the heart muscle that can lead to heart failure in children and adults. […]